Feb 25, 2021
CNS Pharmaceuticals Berubicin Trial is On Schedule to Commence in March 2021
Jan 07, 2021
CNS Pharmaceuticals to Present at the H.C. Wainwright BioConnect 2021 Conference
Dec 23, 2020
CNS Pharmaceuticals Announces Pricing of $10.0 Million Public Offering
Dec 18, 2020
CNS Pharmaceuticals Call to Discuss FDA IND Approval and Phase 2 Trial for Berubicin Today at 8:30am ET
Dec 17, 2020
CNS Pharmaceuticals Announces FDA Approval of IND Application for its Brain Cancer Drug Candidate Berubicin
Nov 19, 2020
CNS Pharmaceuticals and WPD Pharmaceuticals to Contribute Sponsorship to 2020 SNO Virtual Meeting
Nov 18, 2020
CNS Pharmaceuticals to Participate in A.G.P.'s Virtual Healthcare Symposium
Nov 17, 2020
CNS Pharmaceuticals Announces FDA Filing of IND for its Brain Cancer Drug Berubicin
Nov 09, 2020
CNS Pharmaceuticals Announces Adaptive Trial Design For Berubicin Phase 2 Clinical Trial To Be Submitted for FDA Review
Oct 29, 2020
CNS Pharmaceuticals Completes Manufacturing of Berubicin for Phase 2 Clinical Trial
Oct 20, 2020
CNS Pharmaceuticals Completes U.S. Manufacturing of Berubicin for Phase 2 Clinical Trial
Oct 12, 2020
CNS Pharmaceuticals Highlights New Balancing Act Segment on Glioblastoma Airing on Lifetime TV
Oct 09, 2020
CNS Pharmaceuticals Begins Manufacturing of Berubicin in Europe
Sep 24, 2020
CNS Pharmaceuticals and Image Analysis Group Partner to Further the Development of Berubicin
Sep 17, 2020
CNS Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Sep 11, 2020
CNS Pharmaceuticals to Present at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference
Sep 03, 2020
CNS Pharmaceuticals Announces US Drug Manufacturing Milestones
Aug 27, 2020
CNS Pharmaceuticals Announces Appointment of Dr. Patrick Wen, Director of Center for Neuro-Oncology at Dana-Farber Cancer Institute, to Science Advisory Board
Aug 25, 2020
CNS Provides FDA Update on IND Filing
Aug 20, 2020
CNS Pharmaceuticals Engages CRO For Phase 2 Berubicin Clinical Trials